Nucleotide-binding domain and leucine-rich repeat-containing protein 3 (NLRP3)

Nucleotide-binding domain and leucine-rich repeat-containing protein 3 (NLRP3), commonly referred to as NLRP3, is a cytosolic pattern recognition receptor in the innate immune system that senses both pathogenic and sterile cellular stress signals[1][2][3][4][5][6]. Upon activation, NLRP3 forms the NLRP3 inflammasome, a multiprotein complex with the adaptor ASC and effector caspase-1, triggering maturation and release of the proinflammatory cytokines IL-1β and IL-18, and inducing pyroptotic cell death[1][2][3][4][5]. NLRP3 is centrally implicated in various inflammatory, infectious, and metabolic diseases. As a validated therapeutic target, NLRP3 is the focus of active drug development efforts aimed at treating autoinflammatory conditions, cardiovascular, and neurodegenerative diseases by modulating its activity or interrupting downstream cytokine effects[5][6]. Various small molecule inhibitors (notably MCC950) and biologics targeting NLRP3 pathways are advancing in clinical studies, with ongoing investigation into safety and efficacy challenges[6].

Other names

NLRP3NOD-like receptor family, pyrin domain containing 3NALP3CryopyrinCIAS1

Direct inhibition of NLRP3 ATPase activity or oligomerization (MCC950); Prevention of inflammasome assembly/activation; Modulation of upstream stress or membrane signals inhibiting NLRP3 activation; Downregulation of proinflammatory cytokine release (via IL-1β or IL-18 blockade)